Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines

2022; Multidisciplinary Digital Publishing Institute; Volume: 11; Issue: 1 Linguagem: Inglês

10.3390/cells11010154

ISSN

2073-4409

Autores

Izabela Natália Faria Gomes, Renato José da Silva Oliveira, Luciane Sussuchi da Silva, Olga Martinho, Adriane Feijó Evangelista, André van Helvoort Lengert, Letícia Ferro Leal, Viviane Aline Oliveira Silva, Stéphanie Piancenti dos Santos, Flávia Caroline Nascimento, André Lopes Carvalho, Rui Manuel Reis,

Tópico(s)

Cholangiocarcinoma and Gallbladder Cancer Studies

Resumo

Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of cetuximab response are known for HNSCC. Herein, we address the molecular mechanisms underlying cetuximab resistance in an in vitro model. We established a cetuximab resistant model (FaDu), using increased cetuximab concentrations for more than eight months. The resistance and parental cells were evaluated for cell viability and functional assays. Protein expression was analyzed by Western blot and human cell surface panel by lyoplate. The mutational profile and copy number alterations (CNA) were analyzed using whole-exome sequencing (WES) and the NanoString platform. FaDu resistant clones exhibited at least two-fold higher IC

Referência(s)